Status
Conditions
Treatments
About
Osteoarthritis (OA) is a highly progressive and debilitating joint disease. Recently, it was demonstrated the existence of an important link between OA inflammation and progression of structural changes. Therapy with intra-articular injection of stromal vascular fraction (SVF) holds great promises and its efficacy could be further augmented with the addition of biological adjuvants. In the present project, we aim at demonstrating that human platelet lysate (HPL) increases the intrinsic beneficial properties of SVF on cartilage regeneration and joint environment. Moreover, we want to verify if SVF-conditioned medium (CM) obtained from SVF primed with HPL yields comparable or superior outcomes than whole SVF.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
OA patients
Exclusion criteria
27 participants in 2 patient groups
Loading...
Central trial contact
Silvia Palombella, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal